Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
Case report plus systematic review of a drug's efficacy in a rare syndrome; clinical question.
This systematic review evaluates a treatment for a clinical syndrome rather than evidence synthesis methodology.
Clinical review of eculizumab in catastrophic antiphospholipid syndrome, not metaresearch.
Abstract
Objective The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS). Methods We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature. Results Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms. Conclusion Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.
Stored with the screening record, where it is evidence for the labels above.
The record
- Venue
- Lupus
- Topic
- Systemic Lupus Erythematosus Research
- Field
- Medicine
- Canadian institutions
- McMaster University
- Funders
- —
- Keywords
- EculizumabThrombotic microangiopathyMedicineAntiphospholipid syndromeCatastrophic antiphospholipid syndromeAtypical hemolytic uremic syndromeMonoclonalInternal medicineComplement systemIntensive care medicineImmunologyMonoclonal antibodyAntibodyDisease
- Has abstract in OpenAlex
- yes